SCHEMBL6887536

SCHEMBL6887536

CC(C)NC(=O)Cn1c(-c2cc(Cl)ccc2F)nc2ccc(N3CCN4CCC3CC4)cc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 18/20 0.49
AVPR1B P47901 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887874 0.93 AVPR1B (0.45) AVPR1AAVPR1B
SCHEMBL6886584 0.91 AVPR1B (0.49) AVPR1AAVPR1B
SCHEMBL6887513 0.89 AVPR1A (0.46) AVPR1AAVPR1B
SCHEMBL2461835 0.89 AVPR1B (0.53) AVPR1AAVPR1B
SCHEMBL6887402 0.88 AVPR1B (0.47) AVPR1AAVPR1B
SCHEMBL6888850 0.88 AVPR1A (0.51) AVPR1AAVPR1B
SCHEMBL6888429 0.88 AVPR1B (0.47) AVPR1AAVPR1B
SCHEMBL6890417 0.88 AVPR1B (0.51) AVPR1AAVPR1B
SCHEMBL6887421 0.87 AVPR1B (0.54) AVPR1AAVPR1B
SCHEMBL6889814 0.87 AVPR1B (0.49) AVPR1AAVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 AVPR1A 125/4885AVPR1B 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.